With effect from June 12, 2024, the units rights in ExpreS2ion Biotech Holding AB will be traded on First North Growth Market. Trading will continue up until and including June 24, 2024. Instrument: Unit rights Short name: EXPRS2 UR Clearing: Bilateral settlement at Euroclear Sweden ISIN code: SE0022088183 Order book ID: 339503 Market Segment: First North STO Tick Size: MiFID II tick size table With effect from June 12, 2024, the paid subscription units in ExpreS2ion Biotech Holding AB will be traded on First North Growth Market. Trading will continue until and including July 16, 2024. Instrument: Paid subscription units Short name: EXPRS2 BTU Clearing: Bilateral settlement at Euroclear Sweden ISIN code: SE0022088191 Order book ID: 339502 Market Segment: First North STO Tick Size: MiFID II tick size table For further information concerning this exchange notice please contact Issuer Surveillance, telephone +46 8 405 70 50, or iss@nasdaq.com Nasdaq Stockholm AB
Aktien»Nachrichten»EXPRES2ION BIOTECH AKTIE»Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of ExpreS2ion Biotech Holding AB (Record Id 265352)
Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of ExpreS2ion Biotech Holding AB (Record Id 265352)
© 2024 GlobeNewswire
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Nasdaq Stockholm AB: New equity right for trading, ExpreS2ion Biotech Holding AB TO11 | At the request of ExpreS2ion Biotech Holding AB, equity rights will be traded
on First North Growth Market as from July 25, 2024.
Security name: ExpreS2ion Biotech Holding AB TO11
--------------------------------------------------
Short... ► Artikel lesen | |
| Mi | Nasdaq Stockholm AB: New equity right for trading, ExpreS2ion Biotech Holding AB TO10 | At the request of ExpreS2ion Biotech Holding AB, equity rights will be traded
on First North Growth Market as from July 25, 2024.
Security name: ExpreS2ion Biotech Holding AB TO10
--------------------------------------------------
Short... ► Artikel lesen | |
| 05.07. | EXPRES2ION BIOTECHNOLOGIES: ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue | ||
| 03.07. | EXPRES2ION BIOTECHNOLOGIES: ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens | ||
| 01.07. | EXPRES2ION BIOTECHNOLOGIES: ExpreS2ion announces final outcome of its rights issue |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.
